S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.50 (-1.90%)
AAPL   161.26 (-1.53%)
MSFT   322.49 (-2.12%)
FB   306.49 (-1.26%)
GOOGL   2,838.20 (-0.74%)
AMZN   3,381.30 (-1.63%)
TSLA   1,011.42 (-6.75%)
NVDA   306.30 (-4.66%)
BABA   112.33 (-7.93%)
NIO   32.07 (-11.41%)
CGC   9.99 (-3.57%)
AMD   143.93 (-4.48%)
GE   92.80 (-2.55%)
MU   81.65 (-1.48%)
T   23.44 (+1.69%)
F   19.11 (-3.82%)
DIS   146.13 (-0.73%)
PFE   54.18 (+2.15%)
AMC   29.00 (-4.23%)
ACB   5.82 (-5.21%)
BA   198.05 (-2.14%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.50 (-1.90%)
AAPL   161.26 (-1.53%)
MSFT   322.49 (-2.12%)
FB   306.49 (-1.26%)
GOOGL   2,838.20 (-0.74%)
AMZN   3,381.30 (-1.63%)
TSLA   1,011.42 (-6.75%)
NVDA   306.30 (-4.66%)
BABA   112.33 (-7.93%)
NIO   32.07 (-11.41%)
CGC   9.99 (-3.57%)
AMD   143.93 (-4.48%)
GE   92.80 (-2.55%)
MU   81.65 (-1.48%)
T   23.44 (+1.69%)
F   19.11 (-3.82%)
DIS   146.13 (-0.73%)
PFE   54.18 (+2.15%)
AMC   29.00 (-4.23%)
ACB   5.82 (-5.21%)
BA   198.05 (-2.14%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.50 (-1.90%)
AAPL   161.26 (-1.53%)
MSFT   322.49 (-2.12%)
FB   306.49 (-1.26%)
GOOGL   2,838.20 (-0.74%)
AMZN   3,381.30 (-1.63%)
TSLA   1,011.42 (-6.75%)
NVDA   306.30 (-4.66%)
BABA   112.33 (-7.93%)
NIO   32.07 (-11.41%)
CGC   9.99 (-3.57%)
AMD   143.93 (-4.48%)
GE   92.80 (-2.55%)
MU   81.65 (-1.48%)
T   23.44 (+1.69%)
F   19.11 (-3.82%)
DIS   146.13 (-0.73%)
PFE   54.18 (+2.15%)
AMC   29.00 (-4.23%)
ACB   5.82 (-5.21%)
BA   198.05 (-2.14%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.50 (-1.90%)
AAPL   161.26 (-1.53%)
MSFT   322.49 (-2.12%)
FB   306.49 (-1.26%)
GOOGL   2,838.20 (-0.74%)
AMZN   3,381.30 (-1.63%)
TSLA   1,011.42 (-6.75%)
NVDA   306.30 (-4.66%)
BABA   112.33 (-7.93%)
NIO   32.07 (-11.41%)
CGC   9.99 (-3.57%)
AMD   143.93 (-4.48%)
GE   92.80 (-2.55%)
MU   81.65 (-1.48%)
T   23.44 (+1.69%)
F   19.11 (-3.82%)
DIS   146.13 (-0.73%)
PFE   54.18 (+2.15%)
AMC   29.00 (-4.23%)
ACB   5.82 (-5.21%)
BA   198.05 (-2.14%)
NASDAQ:ALNA

Allena Pharmaceuticals Stock Forecast, Price & News

$0.61
-0.05 (-7.19%)
(As of 12/3/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.61
$0.64
50-Day Range
$0.64
$1.00
52-Week Range
$0.62
$2.78
Volume
35,119 shs
Average Volume
2.37 million shs
Market Capitalization
$50.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
30 days | 90 days | 365 days | Advanced Chart
Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Allena Pharmaceuticals logo

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALNA
Employees
41
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.44 per share

Profitability

Net Income
$-32.85 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
74,231,000
Market Cap
$50.43 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

730th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

113th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

Is Allena Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals
or view top-rated stocks.

How has Allena Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNA shares have decreased by 51.5% and is now trading at $0.6107.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,210,000 shares, an increase of 95.7% from the October 31st total of 1,640,000 shares. Based on an average trading volume of 3,170,000 shares, the short-interest ratio is presently 1.0 days.
View Allena Pharmaceuticals' Short Interest
.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Allena Pharmaceuticals
.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) released its earnings results on Wednesday, November, 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01.
View Allena Pharmaceuticals' earnings history
.

What price target have analysts set for ALNA?

2 brokers have issued 1-year target prices for Allena Pharmaceuticals' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 1,128.1% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Louis Brenner, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Geoffrey A. Swire, COO & Senior Vice President-Corporate Development
  • Richard D. Katz, Chief Financial & Accounting Officer
  • David J. Clark, Chief Medical Officer
  • Hugh Wight, Senior Vice President-Technical Operations

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Altium Capital Management LP (1.33%), Geode Capital Management LLC (0.41%), GSA Capital Partners LLP (0.19%), Kestra Advisory Services LLC (0.13%), Two Sigma Securities LLC (0.10%) and Jane Street Group LLC (0.07%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals
.

Which institutional investors are buying Allena Pharmaceuticals stock?

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Altium Capital Management LP, GSA Capital Partners LLP, Two Sigma Securities LLC, Jane Street Group LLC, Quilter Plc, Natixis, Spire Wealth Management, and Geode Capital Management LLC.
View insider buying and selling activity for Allena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $0.61.

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals has a market capitalization of $50.43 million. The company earns $-32.85 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Allena Pharmaceuticals have?

Allena Pharmaceuticals employs 41 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Where are Allena Pharmaceuticals' headquarters?

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at (617) 467-4577, via email at [email protected], or via fax at 617-916-1871.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.